State-of-the-Art Review: Anatomical and Imaging Considerations During Transcatheter Tricuspid Valve Repair Using an Annuloplasty Approach

Abstract

Transcatheter techniques for the treatment of tricuspid regurgitation (TR) are being more frequently used and several new devices are in development. Since 90% of patients with TR have secondary TR, catheter based systems which reduce the dilated tricuspid annulus area are of particular interest. In order to perform an annuloplasty procedure effectively and safely, knowledge about the anatomy of the tricuspid valve apparatus and especially of the annulus in relation to the important neighboring structures such as the aortic root, the RCA, the electrical pathways and the CS is fundamental. In addition, comprehensive understanding of the device itself, the delivery system, its maneuverability and the individual procedural steps is required. Furthermore, the use of multi-modality imaging is important. For each step of the procedure the appropriate imaging modality as well as the optimal; imaging planes are crucial to provide the necessary information to best guide the individual procedural step.

Introduction

In recent years, interest in the transcatheter treatment of tricuspid regurgitation (TR) has considerably increased. TR (including all grades of severity) is a common valve disorder that affects 65–85% of adults (1, 2). In ~90% of all cases TR is functional, being secondary TR due to tricuspid annular dilation with or without leaflet tethering causing malcoaptation (3, 4). Most commonly this is a consequence of left-sided valvular or myocardial disease (>60% of cases) or associated with pulmonary hypertension. In ~10% of all patients with TR, TR is primary (organic) with an intrinsic abnormality of the tricuspid valve itself, which can be either congenital or acquired (3, 5). Primary TR occurs in association with Ebstein‘s anomaly, atrioventricular septal defects or with myxomatous valvular changes resulting in tricuspid valve prolapse. Acquired TR may be caused by endocarditis, rheumatic disease, carcinoid, infiltrative valvulopathy or by an iatrogenic trauma [e.g., by right ventricular (RV) pacemaker leads/RV myocardial biopsy (6–8)]. The prevalence of TR increases with age and is significantly more common in women (9). Mild TR is ubiquitous and not considered pathological as it does not cause RV dysfunction, RV dilation or worsen prognosis

(9). However, moderate or greater TR was identified as independently associated with increased mortality in a study that examined the influence of a TR on hospitalization for heart failure and mortality in 33,305 patients (10). The majority of patients with TR are treated medically, with drug therapy options essentially limited to diuretics and vasodilators in selected patients (11). In the United States only a small number of patients (<8,000 of 1.600.000 patients with moderate-to-severe TR) undergo tricuspid valve surgery (either valve repair or replacement) (12, 13), The low incidence of surgery is thought to be due to outcomes associated with surgical therapy of an isolated TR:

• The in-hospital mortality rate is currently 8.8% (14)

• Isolated tricuspid valve procedures carry the highest risk of all valve surgeries (15)

• Single center experiences with isolated tricuspid valve surgery are limited by small numbers (16)

• The length-of-stay is relatively long: median 11 days (associated with higher costs) (14)

• Pacemakers are utilized in a high number of patients undergoing TV replacement (26%) (14)

• Tricuspid valve replacement, age >60 years, end-stage renal disease and coagulopathies are associated with greater in-hospital mortality (14)

In accordance with current guidelines (11, 17), 86% of tricuspid valve surgeries are performed in patients with other surgical indications whereas surgeries in patients with isolated TR are less common (14%) (18). Mortality rates range between 2 and 10% after isolated tricuspid valve intervention. Prognostic data are limited and do not show improved survival after surgical tricuspid valve repair or replacement (19–21). Hence, new, less invasive therapies to treat TR are needed. A propensity-matched case-control study by Taramasso et al. (22) recently showed promising results. The authors demonstrated, that transcatheter tricuspid valve intervention using different devices and approaches is associated with improved survival and reduced heart failure rehospitalization compared to medical therapy (22).

Since secondary (functional) TR accounts for 90% of the cases in adults, annular dilation is a primary target for therapeutic transcatheter repair strategies. Consequently devices which reduce tricuspid annular dimensions are of interest.

In this review we focus on the annuloplasty approach using the Cardioband (Edwards Lifesciences, Irvine, CA, USA). The Cardioband is the only annuloplasty device with Conformitié Européenne (CE) mark approval. Results from the TRI-REPAIR (TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System) study demonstrated a significant reduction in TR by reducing annular dimensions [the effective regurgitant orifice area was reduced by 50% (0.8 vs. 0.4 cm²; p < 0.01), and the mean vena contracta width by 28% (1.2 vs. 0.9 cm; p < 0.01)] with improvement in heart failure symptoms, quality of life and exercise tolerance after 6 months (23).

In this overview we describe important anatomical structures and anatomical relationships that are relevant for the procedure and a practical guide to peri- procedural imaging according to our initial experiences with the Cardioband device.

Anatomy of the Tricuspid Valve and Relationships to Surrounding Structures

The tricuspid valve is a complex of interconnected components that includes leaflets hinged at the atrioventricular junction and suspended by tendinous chords (chordae tendinea) attached to the ventricular septum or to papillary muscles that, in turn arise from the ventricular wall. At the hinge of the leaflets, atrial myocardium may overlap the leaflet surface by 0.5–2 mm. Thus, normal valvular function requires not only normality of all the valvular components but also adjoining atrial and ventricular walls for sphincteric contraction and excursion of the orifice toward the ventricular apex, as well as interaction with the left ventricle through muscular continuity.

Tricuspid “Annulus” or Atrioventricular Junction?

It is underappreciated that the tricuspid annulus is not a robust fibrous ring which suspends the leaflets. Anatomically, the fibrous tricuspid annulus is indistinct and incomplete, especially at the segment corresponding to the RV “free wall” accounting for the potential dilatation in these regions whereas the “septal” segment is less prone to dilatation. The so-called annulus i.e., the hinge line of the leaflets normally circumscribes an almost oval and non-planar shape that becomes more circular as the RV dilates. Furthermore, its geometry can also be distorted e.g., in dilatation of right atrium (RA), RV as well as aortic root dilatation.

Imaging protocols have arbitrarily divided into 5 segments the tricuspid annulus beginning with segment 1 in the region of the antero-septal commissure and going clockwise to segment 5 at the postero-septal commissure to assess the annulus (24) (Figure 1A). In this classification the septal part of the tricuspid annulus, was separated out. Thus, the annulus along the septal leaflet is further described as segment 6. It should be noted, however, that there is significant variability in the number of leaflets (25) and lengths of the hinge line for each leaflet.

Figure 1

The border between RA and RV wall, the atrioventricular junction, is a wedge of tissue comprised mainly of epicardial fat intermingled with thin collagen and elastic fibers filling the atrioventricular groove (Figure 1B). This tissue is an insulating plane preventing atrial signals from directly reaching ventricular myocardium and it also contributes to the annulus of the leaflets. The right coronary artery (RCA) and its branches, and coronary veins course within the fibro-fatty tissues at variable distances and levels relative to the annulus. An anatomical study reported the distance of the RCA to the endocardial surface of the RA as furthest at segment 2 (5.3 ± 1.3 mm), closer at segment 3 (5.0 ± 2.2 mm), and closest at segment 4 (1.8 ± 0.6 mm) but did not take account of relative level from annulus (26).

The atrial wall leading to the tricuspid orifice is termed the vestibule of the RA. Its endocardial surface is smooth, separating the pectinated appendage wall from the valve orifice (Figure 1B). The portion of the vestibule corresponding to segment 5 is part of the cavo-tricuspid isthmus targeted by electrophysiologists for ablating atrial flutter. Normally the wall thickness of the vestibule is 2–3 mm, thinner in RA dilatation, and tapers considerably as it nears the annulus where it may overlap the leaflet surface (Figure 1A).

Leaflets and Commissures

Supported by fan-shaped commissural chords, the commissures (or breach) do not reach the annulus but several millimeters of leaflet tissue remain sometimes in the form of small scallops. Although tricuspid by name, anatomically there are more commonly five leaflets (25). In addition there is also considerable variation of leaflet shape and length as well as in the presence and number of scallops (25).

All leaflets have a basal clear zone usually devoid of chordal support and a rough zone where majority of tendinous chords insert to the ventricular surface. The rough zone occupying several millimeters from the free edge corresponds to the zone of coaptation that allows the leaflets to abut together and seal the tricuspid valve orifice (Figure 1B).

The septal leaflet, as its name implies, has multiple chordal attachments directly to the ventricular septum or to multiple small papillary muscles that insert to the septum that limit excursion of its movement to close the valvular orifice (Figure 1C).

As shown in Figure 1C the inferior annulus corresponds to segment 5. The remainder of its annulus corresponds to segment 6 and part of segment 1. Although segment 6 is not deemed relevant to current transcatheter devices, it is important to understand its relationship with the cardiac conduction system, the central fibrous body, membranous septum, and the aortic root.

From the postero-septal commissure, the annulus of the septal leaflet ascends superior to be anchored to the central fibrous body which comprises of the right fibrous trigone in the region of aortic-mitral continuity and the membranous septum. This part of the annulus marks the anterior border of the triangle of Koch which is the anatomical landmark for the location of the atrioventricular node and the penetrating bundle of His sitting at its apex. The posterior border of the triangle is marked by the tendon of Todaro while the inferior border is the vestibular wall anterior to the orifice of the coronary sinus (CS) (Figure 1C). Where the annulus crosses the membranous septum superiorly to the apex of Koch's triangle, it divides the membranous septum into two components: an atrioventricular portion that separates the RA from the left ventricle (LV), and an interventricular portion that separates the two ventricles. Furthermore, the leaflet at the membranous septum may take various morphologies sometimes with accessory tissues or is partially or totally deficient thereby potentially leaving a gap in the closure line (Figure 1Ca).

Notably, where segment 6 transitions to segment 1, the septal leaflet extends laterally beyond the membranous septum at the antero-septal segment of the annulus, often appearing as a scallop that adjoins the anterior (aka antero-superior) leaflet at the commissure which is supported by the medial papillary muscle attached to the septomarginal trabeculation (septal band). Importantly, the annulus from the membranous septum to the antero-sepal commissure is related to the aortic root. On the epicardial side, the RA wall is only separated from the non- and right coronary aortic sinuses to varying extents by the transverse pericardial sinus (Figure 1Cb).

The anterior leaflet is the most extensive around the annulus, covering segments 1 through 3, and also the largest, hence contributing the most to the closure of the valvular orifice. It is usually supported by a large anterior papillary muscle that attaches to the moderator band at its insertion to the RV free wall.

Corresponding to segment 4, the posterior (or mural) leaflet is smaller, often supported by a cluster of slender papillary muscles. In some hearts the commissure between the anterior and posterior leaflets is indistinct, giving the impression of a bi-leaflet tricuspid valve while in some the leaflet is scalloped.

In segment 5, the annulus from the postero-septal commissure to continue into the septal annulus runs anterior to the orifice of the CS separated by the vestibule. The distance of the CS orifice to the annulus varies from a few millimeters to 1.5 cm or more. The vestibule may give the impression of a shelf when the orifice is located more toward the septum. This segment of the vestibule is significant in that it marks the inferior border of the anatomical landmark used for locating the atrioventricular node of the cardiac conduction system. It is the target zone for slow pathway ablation in atrioventricular nodal reentry tachycardia as it harbors the rightward inferior extension of the atrioventricular node that usually runs close to the annulus (27) (Figure 1Cb).

Features Important for Percutaneous as Well as Surgical TV Intervention

• The RCA runs within the tissues of the atrioventricular junction at variable levels relative to the level of the leaflet annulus. Its distance from the endocardial surface of the atrium tends to be closer when it courses into the inferior segment (1.8 ± 0.6 mm) compared to its antero-lateral course (5.3+1.3 mm) (26).

• The atrioventricular node at the apex of the triangle of Koch and the conduction bundle at the border of the membranous septum with the ventricular septum. Inferior extensions of the atrioventricluar node at the annulus close to CS orifice.

• Thin RA wall at vestibule surrounding the orifice.

• Location of the aortic root.

The Cardioband Tricuspid Valve Reconstruction System

The tricuspid Cardioband (Edwards Lifesciences, Irvine, CA, USA; (Figure 2) (28) consists of a polyester sleeve containing a pre-mounted contraction wire that is connected to an adjusting spool. On the polyester sleeve radiopaque markers are applied at a distance of 8 mm. Dependent on the length of the selected band 12–17 anchors (these are screws with a length of 6 mm and a width of 2.4 mm) are deployed along the annulus under general anesthesia and 2D/3D transesophageal echocardiography (TEE) and fluoroscopic guidance starting at the antero-septal commissural area to the postero-septal commissural region. For each implanted anchor the correct positioning must be confirmed by 2D/3D TEE and fluoroscopic imaging and a pull test is used in addition to ensure secure insertion before releasing the anchor.

Figure 2

Once all anchors are deployed, the implant delivery system (IDS) is detached from the band and removed. A leading wire stays in place and the size adjustment tool (SAT) is inserted over the wire and connected to the spool. The implant is then contracted stepwise depending on the band size between 3.5 and 5.5 cm under beating heart conditions. TR reduction is assessed in real-time (RT) by TEE monitoring until a satisfactory result is achieved. The implant is then detached from the SAT and the entire system is removed.

Pre-procedural Imaging

Before a procedure the exact mechanism(s) of TR, the grade of TR severity, the precise dimensions of the tricuspid annulus, the localization and extension of calcification as well as relationships of the tricuspid annulus to surrounding structures (particularly the RCA), need to be evaluated. For each anchor position it should be confirmed, that tissue quality is adequate and that there is enough space between the hinge points of the leaflets and coronary vessels to guarantee safe anchoring. As a wire in the RCA is extremely useful for procedural navigation, patency of the RCA is important, and occlusion of this vessel should be excluded prior to the procedure. Furthermore, factors that may affect imaging quality during the procedure should be addressed (see Table 1).

Table 1 summarizes the main imaging views needed before the Cardioband procedure and the imaging modalities that are primarily used for this purpose.

The pre-procedural diagnostic work-up currently includes the following imaging modalities:

Transthoracic (TTE) and Transesophageal Echocardiography (TEE)

TTE is the primary imaging modality to characterize tricuspid valve anatomy, valve lesion(s), valve function, to grade TR severity (17, 29), to evaluate RA and RV size and function (30, 31), to estimate pulmonary artery systolic pressure (32, 33) and to assess specific inclusion/exclusion criteria [inclusion and exclusion criteria used for the TRI-REPAIR study (23) are summarized in Table 2] prior to a procedure. Multiple 2D TTE views should be obtained for a comprehensive evaluation of the right heart. The advantages and limitations of each view must be known to avoid procedural errors (33, 34).

The grading of TR is made according to current guidelines (11, 17) by using a multi-parametric approach. In this context, it is recommended to include 3D vena contracta area measurements in the quantification process (34). However, when using this method, it should be noted that due to the highly complex three-dimensional structure of the anatomical regurgitation surface area of TR, a single plane measurement may not accurately demonstrate the true anatomical orifice. Recently, an extended grading scale to better characterize TR severity prior to a transcatheter procedure has been proposed, including the new grades “massive” and “torrential” TR (35) (echocardiographic parameters indicating severe, massive and torrential TR are summarized in Table 3). Although this extended scale is not evidence-based, it may be useful to help better characterize the effect of transcatheter intervention on the TR grade. In addition, natural history studies show, that the prognosis of patients with “very severe” TR is significantly worse compared to patients with “severe” TR, thus suggesting, that any reduction of TR may result in improved outcomes and a reduction of mortality (36). However, long-term outcomes related to reduction in TR after transcatheter procedures are not currently available.

RT 3D echocardiography adds valuable information and supplements 2D echocardiography. By providing enface views of the tricuspid valve the number, size and mobility of leaflets, the attachment of the leaflets to the tricuspid annulus, leaflet coaptation, commissural opening, annular shape, and size can be evaluated during the cardiac cycle in a single view and 3D volumes can be provided (37–40).

The imaging of the tricuspid valve with TEE is generally more difficult than the mitral valve (MV). The tricuspid valve is located more anterior and thus further away from the TEE probe. Secondly, the tricuspid valve inserts more apically than the MV. Deep esophageal views often have a poorer quality because the esophagus curves away from the heart in its distal segment. Thirdly, tricuspid valve leaflets are thinner than the MV leaflets and visualization is therefore more difficult and echo drop out artifact frequently occur. Furthermore, acoustic windows are limited and fibrous/lipomatous structures in the heart as well as any prosthetic material in the left heart (e.g., prosthetic valves), at the interatrial septum (e.g., atrial septal occluders or patent foramen ovale occluders) or in the right heart (e.g., pacemaker/defibrillator leads) may cause acoustic shadowing or reverberations in the far field of the image and thus overshadow/obscure the tricuspid valve. Acoustic shadowing can usually be overcome in part by using trans-gastric windows, therefore it is important to check trans-gastric imaging quality and ensure, that the entire circumference of the annulus is visible prior to the procedure, optimally in supine position.

2D and 3D TEE imaging of the tricuspid valve is described in detail in current guidelines (41) and state-of-the art papers (39).

In our experience, the most important TEE views to assess the tricuspid valve prior to a Cardioband procedure and to guide the procedure include mid- (4-chamber) and deep esophageal views at 0–10°, a mid-esophageal RV inflow-outflow view (50–70°), trans-gastric views and 3D enface views of the tricuspid valve as shown in Figures 3–7.

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Multi-Detector Computed Tomography (MDCT)

MDCT is the preferred imaging modality to depict degenerative calcium deposition in the tricuspid annulus. This is rare in the tricuspid compared to mitral valve disease and occurs usually secondary to diffuse cardiac calcinosis, in patients with longstanding severe kidney disease and chronic dialysis and in patients with chronic inflammatory diseases (e.g., rheumatic heart disease) (42, 43). However, if present, secure anchoring in affected regions may be hindered and patients with relevant annular calcification should therefore be excluded.

Furthermore, MDCT is used prior to a tricuspid Cardioband procedure to measure annular dimensions, to define the position of the first anchor place, to select an appropriate band size, to evaluate the tissue quality and the distance to the hinge points of the leaflets and the RCA for each anchor region, to pre-define optimal fluoroscopic projections for a specific patient (Figure 8), and to identify the position of RV pacemaker/defibrillator leads at the level of the tricuspid valve and to detect related complications (44). However, MDCT has technical limitations in showing all tricuspid leaflet positions at a specific time frame of the cardiac cycle (45).

Figure 8

Cardiac Magnetic Resonance (CMR) Imaging

CMR imaging is accurate and reproducible in the evaluation of RV morphology, size, and function and allows for the non-invasive assessment of blood flow, including stroke volume, cardiac output, pulmonary arterial distensibility and RV mass and can therefore play an important role in the decision-making process, particularly when TTE/TEE findings are ambiguous (46).

Coronary Angiography and Right Heart Catheterization

A coronary angiography is needed prior to a procedure in order to exclude coronary artery disease. Especially the patency of the RCA should be ensured, since the placement of a coronary wire in this vessel considerably facilitates the navigation during the procedure Echocardiographic evaluation of pulmonary artery hypertension includes: a peak TR systolic velocity >2.9 m/s, an RV/LV basal diameter ratio >1, flattening of the interventricular septum in systole and/or diastole, an RV acceleration time <105 ms and/or mid-systolic notching, an early diastolic pulmonary regurgitation velocity >2.2 m/s, a pulmonary artery diameter >25 mm, an inferior cava diameter >21 mm with decreased inspiratory collapse and an end-systolic RA area >18 cm².

Severe TR may cause equalization of RA and RV pressures which can result in low TR systolic velocities, leading to underestimation of pulmonary artery systolic pressures by echocardiographic Doppler evaluation (47). Consequently, a right heart catheterization should be performed to more precisely assess pulmonary pressure and the severity of hemodynamic impairment (32).

It can also result in underestimation of pulmonary artery mean pressures during right heart catheterization even in case of considerably elevated pulmonary vascular resistance. The measurement of pulmonary vascular resistance should therefore be included in the right heart catheter examination.

Intraprocedural Imaging

The procedure is currently guided with 2D/3D TEE imaging in conjunction with fluoroscopy. Intracardiac echocardiography (ICE) has shown to be feasible for the guidance of some tricuspid procedures (48, 49) and may also be helpful during annuloplasty approaches, particularly in cases where TEE imaging is suboptimal. By positioning the ICE catheter in a steerable sheath at the level of the tricuspid valve adequate imaging to guide device positioning is achievable to our experience. The fusion of different imaging modalities, e.g., fluoroscopy and TEE imaging (EchoNavigator, Philips Healthcare, Best, the Netherlands) (39) or MDCT and TEE imaging (CT Fusion, GE Healthcare, Amersham, UK) (50) has the potential to better understand the complex anatomy of the tricuspid valve and the relationships to surrounding structures, wires, catheters and devices during procedures in future.

Procedural Steps

Before starting the procedure 2D/3D TEE is used to re-assess annular dimensions and TR severity. This is of utmost importance as TR grade and annular dimensions are dynamic and can vary considerably in size depending on the volume status of the patient (e.g., in patients that have been fasting prior to the procedure) which may be different at the moment of the procedure compared to the point in time when MDCT derived measurements for band size selection were made. Thus, the correct band size needs to be confirmed (Figure 9). In addition, a wire [e.g., a Runthrough NS guidewire (Terumo Medical, Tokyo, Japan), or a Whisper MS guidewire (Abbott Vascular, North Chicago, IL, USA)] is positioned in the RCA to facilitate navigation during the procedure by using standard catheter techniques.

Figure 9

Introduction of the Transfemoral Steerable Sheath and the Implant Delivery System

In a first step, the transfemoral steerable sheath (TSS) with a dilator is introduced into the RA or directly into the superior caval vein (SVC) under fluoroscopic and TEE guidance by using a transfemoral venous access. In the next step, the implant delivery system (IDS) consisting of the steerable Guide catheter (GC) and the implantation catheter (IC; can only be retracted or advanced and is not steerable) is inserted and positioned in the SVC. These steps are best monitored by using 2D TEE bicaval views with x-plane imaging or alternatively 3D TEE views obtained from a bicaval view (Figure 10A). The entire system is then retracted until TEE imaging confirms, that the tip of the IDS is no longer in the SVC and the delivery system is then navigated downwards toward the antero-septal commissural area of the tricuspid annulus to reach the first anchor position.

Figure 10

Device Implantation

In general, 3D TEE enface views of the tricuspid valve are used to navigate the delivery system around the tricuspid annulus to the target region. Once an anchor point is reached, x-plane imaging or RT multi-planar reconstruction (RT-MPR) of a 3D data set is subsequently used to confirm contact of the IC tip to the annulus, adequate distance of the IC tip to the hinge point of the leaflets and coronary vessels, an adequate angulation of the delivery system in relation to the annular plane and satisfactory tissue quality for anchoring. After the correct position is confirmed by TEE and fluoroscopy, the anchor is screwed in and subsequently a tug- test is performed to ensure stable anchorage. During the tug- test attention must be paid to the annular tissue movement at the anchor point (visible in TEE), alternatively a relative movement between the GC and IC can be considered as an indirect sign of secure anchoring (visible in TEE and fluoroscopy). If the anchor position is satisfactory the anchor is released and by releasing the band the next anchor position is targeted. All further anchors are implanted in the same way along the tricuspid annulus. The procedural steps are illustrated in Figure 10 and specific anatomical and imaging considerations for anchor placement in the different annular regions are summarized in Table 4.

Contraction of the Implant

Once all anchors are implanted the IDS is retrieved and the SAT is inserted over the wire and connected to the spool. The contraction is performed step-wise and the effect on the TR grade and annular dimensions is monitored by TEE preferably by using x-plane imaging with color Doppler of the TR jet under beating heart conditions as shown in Figure 11 until a satisfactory result or the maximum possible contraction for the selected band size is reached.

Figure 11

Assessment of Final Result

Before the device is detached from the SAT annular dimensions and the grade of TR are re-assessed in the same way as before and a coronary angiography is performed to confirm unlimited flow in the RCA. If needed, the band can be partially or completely released prior to detachment. If the result is satisfactory, the implant is detached from the SAT and the entire system is retrieved through the femoral vein.

Detection of Complications

Complications may occur at any time point during the procedure. These include the formation of thrombi either in the cardiac chambers or attached to wires/catheters/devices, the occurrence of pericardial effusion/tamponade or a peri-device leak, anchor disengagement, injury of the RCA or cardiac veins including the CS, injury of tricuspid leaflets, arrhythmias, particularly higher grades of AV blocks, or RA/RV/defibrillator lead dislodgement. Thus, continuous, detailed and active TEE monitoring, as well as ECG and hemodynamic monitoring is required to immediately detect any of these complications.

Specific Considerations in Patients With Pacemaker/Defibrillator Leads

If pacemaker/defibrillator leads are present, certain questions must be answered:

• How many leads are present?

• Is one of the leads relevantly involved in the mechanism of TR?

  • ∘ If yes, the primary consideration should be to revise the lead to improve the TR

• If a RA lead is present, where is the tip located?

  • ∘ Most RA leads are located in the anterior region close to the right atrial appendage. In this case it is usually easy to navigate the delivery system to the lateral side of the lead. If the RA lead is located at the lateral wall, it is necessary to insert the delivery system inferior to the RA lead to avoid any interference with the delivery system

• Where are the RV/defibrillator leads located at the level of the Tricuspid valve and are the leads mobile or attached to the annulus/to a tricuspid leaflet/to the RA lead?

  • ∘ In general, the delivery system should be navigated to the lateral/anterior side of the RV/defibrillator leads to avoid any interference

  • ∘ If a lead is mobile it is usually possible to push the leads toward the poster-septal commissure and to avoid any interference with the delivery system.

  • ∘ If it is not possible to navigate the system to the lateral/anterior side of the RV/defibrillator leads or if the lead(s) are attached to the annulus, to each other or to leaflets, a careful analysis should be done, to decide whether the procedure can be performed without endangering the pacemaker/defibrillator leads.

• Are there any thrombi attached to the leads?

  • ∘ Mobile thrombi attached to pacemaker leads are frequent and occur in up to 30% of patients undergoing ablation therapy (52). If a patent foramen ovale is present in addition, a higher risk of stroke may be present (53).

Conclusion

Secondary TR is the most common etiology occurring in about 90% of patients with severe TR. Therefore, interventional approaches that target the mechanistic causes of secondary TR in the form of annulus reduction are particularly important. In order to perform an annuloplasty procedure effectively and safely, a good understanding of the anatomy of the complex tricuspid valve apparatus and especially of the annulus in relation to the important neighboring structures such as the aortic root, the RCA, the electrical pathways and the CS is fundamental. In addition, detailed knowledge of the device itself, the delivery system, its maneuverability and the individual procedural steps is required. Furthermore, the use of multi-modality imaging is extremely important. For each step of the procedure, the imaging modality and the optimal imaging planes that are best suited to provide the necessary information are essential to guide the individual procedural step and lead to a safe, successful, and effective procedure.

References

• 1.

  DemirOMRegazzoliDMangieriAAnconaMBMitomoSWeiszGet al. Transcatheter tricuspid valve replacement: principles and design. Front Cardiovasc Med. (2018) 5:129. 10.3389/fcvm.2018.00129

  • CrossRef
  • Google Scholar

• 2.

  SinghJPEvansJCLevyDLarsonMGFreedLAFullerDLet al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the framingham heart study). Am J Cardiol. (1999) 83:897–902. 10.1016/S0002-9149(98)01064-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3.

  MutlakDLessickJReisnerSAAronsonDDabbahSAgmonY. Echocardiography-based spectrum of severe tricuspid regurgitation: the frequency of apparently idiopathic tricuspid regurgitation. J Am Soc Echocardiogr. (2007) 20:405–8. 10.1016/j.echo.2006.09.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4.

  MangieriAMontaltoCPagnesiMJabbourRJRodes-CabauJMoatNet al. Mechanism and implications of the tricuspid regurgitation: from the pathophysiology to the current and future therapeutic options. Circ Cardiovascu Intervent. (2017) 10:e005043. 10.1161/CIRCINTERVENTIONS.117.005043

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5.

  TopilskyYMaltaisSMedina InojosaJOguzDMichelenaHMaaloufJet al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging. (2019) 12:433–42. 10.1016/j.jcmg.2018.06.014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6.

  HokeUAugerDThijssenJWolterbeekRvan der VeldeETHolmanERet al. Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up. Heart. (2014) 100:960–8. 10.1136/heartjnl-2013-304673

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7.

  ChangJDManningWJEbrilleEZimetbaumPJ. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol. (2017) 69:2331–41. 10.1016/j.jacc.2017.02.055

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8.

  KobzaRKurzDJOechslinENPrêtreRZuberMVogtPet al. Aberrant tendinous chords with tethering of the tricuspid leaflets: a congenital anomaly causing severe tricuspid regurgitation. Heart. (2004) 90:319–23. 10.1136/hrt.2002.006254

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9.

  NathJFosterEHeidenreichPA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. (2004) 43:405–9. 10.1016/j.jacc.2003.09.036

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  ChorinERozenbaumZTopilskyYKonigsteinMZiv-BaranTRichertEet al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging. (2020) 21:157–65. 10.1093/ehjci/jez216

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11.

  NishimuraRAOttoCMBonowROCarabelloBAErwinJPIIIFleisherLAet al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. (2017). 135:e1159–95. 10.1161/CIR.0000000000000503

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12.

  StugeOLiddicoatJ. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg. (2006) 132:1258–61. 10.1016/j.jtcvs.2006.08.049

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13.

  IngrahamBSPislaruSVNkomoVTNishimuraRAStulakJMDearaniJAet al. Characteristics and treatment strategies for severe tricuspid regurgitation. Heart. (2019) 105:1244–50. 10.1136/heartjnl-2019-314741

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14.

  ZackCJFenderEAChandrashekarPReddyYNVBennettCEStulakJMet al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol. (2017) 70:2953–60. 10.1016/j.jacc.2017.10.039

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15.

  RankinJSHammillBGFergusonTBJrGlowerDDO'BrienSMDeLongERet al. Determinants of operative mortality in valvular heart surgery. J Thorac Cardiovasc Surg. (2006) 131:547–57. 10.1016/j.jtcvs.2005.10.041

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16.

  OhTHWangTKSidhuKHaydockDA. Isolated tricuspid valve surgery at a single centre: the 47-year Auckland experience, 1965-2011. Interact Cardiovasc Thorac Surg. (2014) 18:27–32. 10.1093/icvts/ivt452

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17.

  BaumgartnerHFalkVBaxJJDe BonisMHammCHolmPJet al. ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. (2017). 38:2739–91. 10.5603/KP.2018.0013

  • CrossRef
  • Google Scholar

• 18.

  KilicASaha-ChaudhuriPRankinJSConteJV. Trends and outcomes of tricuspid valve surgery in North America: an analysis of more than 50,000 patients from the Society of thoracic surgeons database. Ann Thorac Surg. (2013) 96:1546–52; discussion 52. 10.1016/j.athoracsur.2013.06.031

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19.

  VassilevaCMShaboskyJBoleyTMarkwellSHazelriggS. Tricuspid valve surgery: the past 10 years from the nationwide inpatient sample (NIS) database. J Thorac Cardiovasc Surg. (2012) 143:1043–9. 10.1016/j.jtcvs.2011.07.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20.

  KimJBJungSHChooSJChungCHLeeJW. Clinical and echocardiographic outcomes after surgery for severe isolated tricuspid regurgitation. J Thorac Cardiovasc Surg. (2013) 146:278–84. 10.1016/j.jtcvs.2012.04.019

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21.

  KwonDAParkJSChangHJKimYJSohnDWKimKBet al. Prediction of outcome in patients undergoing surgery for severe tricuspid regurgitation following mitral valve surgery and role of tricuspid annular systolic velocity. Am J Cardiol. (2006) 98:659–61. 10.1016/j.amjcard.2006.03.047

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22.

  TaramassoMBenfariGvan der BijlPAlessandriniHAttinger-TollerABiascoLet al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. (2019) 74:2998–3008. 10.1016/j.jacc.2019.09.028

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23.

  NickenigGWeberMSchuelerRHausleiterJNäbauerMvon BardelebenRSet al. 6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol. (2019). 73:1905–15. 10.1016/j.jacc.2019.01.062

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24.

  AgricolaEAnconaFStellaSRosaIMariniCSparteraMet al. Use of echocardiography for guiding percutaneous tricuspid valve procedures. JACC Cardiovasc Imaging. (2017) 10(10 Pt A):1194–8. 10.1016/j.jcmg.2016.10.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25.

  LamaPTamangBKKulkarniJ. Morphometry and aberrant morphology of the adult human tricuspid valve leaflets. Anat Sci Int. (2016) 91:143–50. 10.1007/s12565-015-0275-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26.

  UedaAMcCarthyKPSánchez-QuintanaDHoSY. Right atrial appendage and vestibule: further anatomical insights with implications for invasive electrophysiology. Europace. (2013) 15:728–34. 10.1093/europace/eus382

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27.

  InoueSBeckerAE. Posterior extensions of the human compact atrioventricular node: a neglected anatomic feature of potential clinical significance. Circulation. (1998) 97:188–93. 10.1161/01.CIR.97.2.188

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28.

  Messika-ZeitounDNickenigGLatibAKuckKHBaldusSSchuelerRet al. Transcatheter mitral valve repair for functional mitral regurgitation using the cardioband system: 1 year outcomes. Eur Heart J. (2019) 40:466–72. 10.1093/eurheartj/ehy424

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29.

  NishimuraRAOttoC. ACC/AHA valve guidelines: earlier intervention for chronic mitral regurgitation. Heart. (2014). 100:905–7. 10.1136/heartjnl-2014-305834

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30.

  GalderisiMCosynsBEdvardsenTCardimNDelgadoVDi SalvoGet al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. (2017) 18:1301–10. 10.1093/ehjci/jex244

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31.

  LangRMBadanoLPMor-AviVAfilaloJArmstrongAErnandeLet al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. (2015) 16:233–70. 10.1093/ehjci/jev014

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32.

  GalièNHumbertMVachieryJLGibbsSLangITorbickiAet al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): Endorsed by: Association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J. (2016) 37:67–119. 10.1093/eurheartj/ehv317

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 33.

  RudskiLGLaiWWAfilaloJHuaLHandschumacherMDChandrasekaranKet al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American society of echocardiography endorsed by the European association of echocardiography, a registered branch of the European society of cardiology, and the Canadian society of echocardiography. J Am Soc Echocardiogr. (2010) 23:685–713; quiz 86–8. 10.1016/j.echo.2010.05.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34.

  HahnRT. State-of-the-Art review of echocardiographic imaging in the evaluation and treatment of functional tricuspid regurgitation. Circ Cardiovasc Imaging. (2016) 9:e005332. 10.1161/CIRCIMAGING.116.005332

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35.

  HahnRTZamoranoJL. The need for a new tricuspid regurgitation grading scheme. Eur Heart J Cardiovasc Imaging. (2017) 18:1342–3. 10.1093/ehjci/jex139

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36.

  SantoroCMarco Del CastilloAGonzález-GómezAMonteagudoJMHinojarRLorenteAet al. Mid-term outcome of severe tricuspid regurgitation: are there any differences according to mechanism and severity?Eur Heart J Cardiovasc Imaging. (2019) 20:1035–42. 10.1093/ehjci/jez024

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37.

  BadanoLPAgricolaEPerez de IslaLGianfagnaPZamoranoJL. Evaluation of the tricuspid valve morphology and function by transthoracic real-time three-dimensional echocardiography. Eur J Echocardiogr. (2009) 10:477–84. 10.1093/ejechocard/jep044

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38.

  LangRMBadanoLPTsangWAdamsDHAgricolaEBuckTet al. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J Am Soc Echocardiogr. (2012) 25:3–46. 10.1016/j.echo.2011.11.010

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39.

  MuraruDHahnRTSolimanOIFaletraFFBassoCBadanoLP. 3-Dimensional Echocardiography in imaging the tricuspid valve. JACC Cardiovasc Imaging. (2019). 12:500–15. 10.1016/j.jcmg.2018.10.035

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40.

  AddetiaKMuraruDBadanoLPLangRM. New directions in right ventricular assessment using 3-dimensional echocardiography. JAMA Cardiol. (2019) 4:936–44. 10.1001/jamacardio.2019.2424

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41.

  HahnRTAbrahamTAdamsMSBruceCJGlasKELangRMet al. Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American society of echocardiography and the society of cardiovascular anesthesiologists. Anesth Analg. (2014) 118:21–68. 10.1213/ANE.0000000000000016

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42.

  SaremiFSánchez-QuintanaDMoriSMuresianHSpicerDEHassaniCet al. Fibrous skeleton of the heart: anatomic overview and evaluation of pathologic conditions with CT and MR imaging. Radiographics. (2017) 37:1330–51. 10.1148/rg.2017170004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 43.

  GouldLZahirMDeMartinoAGomprechtRFHaytD. Extensive calcification of the tricuspid valve in rheumatic heart disease. Angiology. (1971) 22:529–32. 10.1177/000331977102200906

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 44.

  BalabanoffCGaffneyCEGhersinEOkamotoYCarrilloRFishmanJE. Radiographic and electrocardiography-gated noncontrast cardiac CT assessment of lead perforation: modality comparison and interobserver agreement. J Cardiovasc Comput Tomogr. (2014) 8:384–90. 10.1016/j.jcct.2014.08.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 45.

  SaremiFHoSYCabreraJASánchez-QuintanaD. Right ventricular outflow tract imaging with CT and MRI: part 1, morphology. AJR Am J Roentgenol. (2013) 200:W39–50. 10.2214/AJR.12.9333

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 46.

  SaremiFHassaniCMillan-NunezVSánchez-QuintanaD. Imaging evaluation of tricuspid valve: analysis of morphology and function with CT and MRI. AJR Am J Roentgenol. (2015) 204:W531–42. 10.2214/AJR.14.13551

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 47.

  ParasuramanSWalkerSLoudonBLGollopNDWilsonAMLoweryCet al. Assessment of pulmonary artery pressure by echocardiography-A comprehensive review. Int J Cardiol Heart Vasc. (2016) 12:45–51. 10.1016/j.ijcha.2016.05.011

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 48.

  BurstowDJWestMLWaltersDL. Intracardiac echo guided valvuloplasty of a stenotic tricuspid prosthetic valve in a patient with idiopathic hypereosinophilic syndrome. Echocardiography. (2006) 23:324–8. 10.1111/j.1540-8175.2006.00214.x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 49.

  VijayaramanPPanikkathR. Intracardiac echocardiography-guided left bundle branch pacing in a patient with tricuspid valve replacement. J Cardiovasc Electrophysiol. (2019) 30:2525–7. 10.1111/jce.14205

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 50.

  FortuniFMarquesAIBaxJJAjmone MarsanNDelgadoV. Echocardiography-computed tomography fusion imaging for guidance of transcatheter tricuspid valve annuloplasty. Eur Heart J Cardiovasc Imaging. (2020) 10.1093/ehjci/jeaa054

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 51.

  MiglioranzaMHMihăilăSMuraruDCucchiniUIlicetoSBadanoLP. Dynamic changes in tricuspid annular diameter measurement in relation to the echocardiographic view and timing during the cardiac cycle. J Am Soc Echocardiogr. (2015) 28:226–35. 10.1016/j.echo.2014.09.017

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 52.

  SuppleGERenJFZadoESMarchlinskiFE. Mobile thrombus on device leads in patients undergoing ablation: identification, incidence, location, and association with increased pulmonary artery systolic pressure. Circulation. (2011) 124:772–8. 10.1161/CIRCULATIONAHA.111.028647

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 53.

  DeSimoneCVFriedmanPANoheriaAPatelNADeSimoneDCBdeirSet al. Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale. Circulation. (2013) 128:1433–41. 10.1161/CIRCULATIONAHA.113.003540

  • CrossRef
  • Google Scholar